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Ethically, it is very diﬃcult to use the classical paradigms of
drug studies in pregnancy, due to the potential fetal risks of
prospective exposure of the mother and fetus to chemicals
for which safety has not been conﬁrmed. This special issue
presentsnewapproachesandoﬀersnovelsolutionstoserious
challenges, from the use of antidepressants in pregnancy to
domperidone in enhancing lactation, fromthe potential fetal
advantagesofpolyunsaturatedfattyacidstothepotentialrisk
of drugs of abuse.
Themajorityofpregnantwomenusemedicationsduring
pregnancy either before recognizing they have conceived or
due to the need to treat medical conditions that may aﬀect
maternal and fetal well-being. Due to the potential fetal risks
of drugs, very few randomized controlled trials are being
conducted in early pregnancy, and the numbers are scarce
even after embryogenesis has been completed. As a result,
women are typically orphaned from the beneﬁts of new ther-
apeutic modalities. Yet, with women tending to postpone
the age of starting a family, substantially larger numbers of
women experience chronic conditions that necessitate drug
therapy.
This issue focuses on major challenges in the area of
drug therapy during pregnancy and lactation, looking for
evidenceofsafetyandeﬀectivenesswiththeuseofavarietyof
research methodologies that try to replace the gold standard
of randomized clinical trials.
O. Diav-Citrin and A. Ornoy tackle what is probably the
biggest contemporary controversy—the fetal safety of anti-
depressants. Through painstaking review of over 30 studies,
they come to the conclusion that fetal and neonatal risks,
even if they exist, occur at very low rates and are outweighed
by the maternal beneﬁts of these drugs.
M.Morettiandcolleaguesfocusonanothercontroversial
area—the fetal safety of ACE inhibitors, commonly used
for hypertension. By including a control group matched for
the hypertensive morbidity, they strengthen the growing
body of evidence suggesting no increased fetal risks after
ﬁrst trimester exposure to ACE inhibitors. With convincing
evidence that neonatal folic acid supplementation and forti-
ﬁcation can prevent neural tube defects, a fear has emerged
that too much circulating folate may increase the risk of
cancer as an adverse eﬀect of unmetabolized folic acid. C.
Tam and colleagues document that levels of unmetabolized
folic acid do not increase in women even when taking
5mg daily. This detailed biochemical study adds important
reassurance that short period use of even 5mg folate (which
is needed in groups of women at high risk for neural tube
defects) is safe to the expecting mother.
S. M. Clark and colleagues update the reader on the
advances in treating the most common condition in preg-
nancy—morning sickness. Even today, a large proportion of
pregnant women are afraid to treat the symptoms of nausea
and vomiting of pregnancy due to unjustiﬁed perception
of fetal risks. S. M. Clark et al. match the evidence of ef-
fectiveness with that of fetal safety, documenting that in 2012
there is no logical reason for a woman not to be managed
safely for this condition.
Breastfeeding is the ideal method of infant nutrition;
however, not rarely women cannot establish eﬀective milk
ﬂow to ensure optimal feeding. Two research papers in2 Obstetrics and Gynecology International
this special issue address this problem, relating directly to
the dopaminergic agent domperidone. A. Osadschy and
colleagues use a meta-analytic technique to provide evidence
that the existing, small studies prove the eﬀectiveness of
the drug in improving milk production. C. Mannion et al.,
bringing the important angle of lactation consultants, ex-
plore in a pilot study determinants of success and failure in
establishing breastfeeding.
Three papers in this issue explore in-depth methodolog-
ical issues which challenge diﬀerent aspects of drug therapy
in pregnancy. B. K¨ all´ en brings his many years of experience
in pharmacoepidemiology to the critical discussion of con-
founders which may aﬀect the interpretation of administra-
tive data bases. These prescription databases, when linked
with databases of pregnancy outcome, create a potentially
powerful tool in exploring fetal safety of drugs. However,
this method is challenged by a large number of serious con-
founders that must be considered and addressed.
D. Matsui tackles one of the most serious issues in drug
therapy in pregnancy—patient compliance. Due to fears of
teratogenicity, expecting women tend not to take their med-
ications as prescribed, even in cases of life-threatening con-
ditions. Deeper understanding of these issues is critical if we
are to improve drug therapy in pregnancy.
One of the biggest ethical issues in pregnancy is how to
gain knowledge on fetal exposure to drugs, when many of
these drugs may be unsafe. C. Gedeon and colleaguesexplore
the ethical and practical implications of giving the mother
a drug just before an elective pregnancy termination and
measuring its kinetics in the abortus.
Itappearsthatscoresofsuchstudieshavebeenconducted
by scientists in diﬀerent countries, but this practice has not
been accompanied by in-depth discussion on its ethical and
legal implication.
Over the last 2 decades a large body of experimental
animal research has documented the role of polyunsaturated
fatty acids (PUFAs) in ensuring normal fetal brain develop-
ment. This research has been mirrored by human studies
suggesting that oﬀspring of women who suﬀer from deﬁcits
in PUFA are lagging in their visual development. This has
led to the commonly held suggestion that enriching the diets
of healthy women who do not exhibit PUFA deﬁciency may
improve oﬀspring brain function. Lo and colleague oﬀer the
ﬁrstsystematicreviewofallrandomizedstudiesinpregnancy
looking at the potential beneﬁts of PUFA supplementation.
The results bring into question voices calling for sweeping
recommendation to supplement with PUFA women who
enjoy normal nutrition.
Lastly, a unique paper by Unger and colleagues tackles
the issues of drug exposure and therapy for women suﬀering
fromaddiction.Withincreasingnumbersofdrug-dependent
women of reproductive age, optimal care of these women
and their unborn children, neonates, and infants should be
am a j o rf o c u s .
We hope that you, the reader, will ﬁnd this special issue
stimulating and, as important, relevant to your practice.
Gideon Koren
Shannon Clark
Doreen Matsui